IDH1 and central nervous system cancer: However, after adjusting for sex, age group, and IDH1 mutation status, the PTPμ high non-GBM glioma patients had significantly longer recurrence free survival times than the PTPμ low non-GBM patients, 34.1 versus 11.8 months, respectively (Figure 6d).